Lijuan Hao

Title: Lijuan Hao: Innovator in Antibody Development

Introduction

Lijuan Hao is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work focuses on innovative solutions for medical challenges, showcasing his expertise and dedication to advancing healthcare.

Latest Patents

Lijuan Hao holds a patent for an IL-13 antibody and its preparation method and use. The invention discloses an IL-13 antibody that includes one or more heavy chain CDRs (complementarity-determining regions) and/or light chain CDRs. This antibody demonstrates high affinity and effectively inhibits the secretion of thymus activation-regulated chemokine and periostin, as well as the expression of vascular cell adhesion molecule-1 induced by IL-13. The IL-13 antibody has shown promise in significantly inhibiting airway hyperresponsiveness in mice induced by IL-13, making it a potential candidate for drug development aimed at preventing or treating IL-13 related diseases. Lijuan Hao has 1 patent to his name.

Career Highlights

Lijuan Hao is associated with Shanghai Pharmaexplorer Co., Ltd., where he continues to work on groundbreaking research and development in the field of antibodies. His career is marked by a commitment to innovation and a focus on improving therapeutic options for patients.

Collaborations

Lijuan Hao collaborates with talented individuals in his field, including Yizhen Yang and Shiyong Gong. These partnerships enhance the research and development process, fostering an environment of creativity and scientific advancement.

Conclusion

Lijuan Hao's contributions to antibody development highlight his role as an innovator in biotechnology. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in the treatment of IL-13 related diseases.